Multiple Myeloma Clinical Trial

A Rollover Study of CC-122

Summary

The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 [NCT01421524], CC-122-ST-002 [NCT02509039], CC-122-DBCL-001 [NCT02031419], and CC-122-NHL-001 [NCT02417285]), receiving clinical benefit from the treatment and to monitor the safety and tolerability of CC-122.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Participant who is currently receiving CC-122 on another CC-122 clinical trial that has met its primary and secondary endpoints.
Participant who has participated in previous CC-122 protocol (including CC-122-ST-001 [NCT01421524], CC-122-ST-002 [NCT02509039], CC-122-DBCL-001 [NCT02031419], and CC-122-NHL-001 [NCT02417285]), and is deemed by the investigator to be deriving benefit from CC-122 as defined by the previous protocol.
Participant who is able to tolerate study therapy and has not yet experienced progressive disease or any treatment discontinuation criteria of the Parent Study.

Key Exclusion Criteria:

Participant is not eligible for CC-122 treatment as per the Parent Study.
Participants not receiving clinical benefit as assessed by the investigator. Any clinical AE, laboratory abnormality, or intercurrent illness which, in the opinion of the investigator, indicates that participation in the study is not in the best interest of the participant.
Women who are breastfeeding.

Note: Other protocol-defined inclusion/exclusion criteria apply.

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

12

Study ID:

NCT05688475

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Weill Medical College Of Cornell University
New York New York, 10065, United States More Info
Ruben Niesvizky, Site 100
Contact
646-258-0156
Sarah Cannon Research Institute
Nashville Tennessee, 37203, United States More Info
Ian Flinn, Site 101
Contact
615-320-5090
University of Wisconsin Carbone Cancer Center
Madison Wisconsin, 53792, United States More Info
Vaishalee Kenkre, Site 102
Contact
608-263-1836
Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest
Bordeaux , 33076, France More Info
Fontanet Bijou, Site 300
Contact
33556333333
Institut Paoli Calmette Hematologie
Marseille cedex , 13273, France More Info
Jean-Marc Schiano De Colella, Site 301
Contact
Local Institution - 500
Koto-ku Tokyo, 13585, Japan
Local Institution - 400
Amsterdam , 1105, Netherlands More Info
Site 400
Contact

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

12

Study ID:

NCT05688475

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.